SCHEMBL12197846

SCHEMBL12197846

O=C(Nc1ccc(S(=O)(=O)Nc2ccc(Cl)cc2)cc1)c1ccccn1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 7/20 0.85
NPC1 O15118 2/20 0.70
RAB9A P51151 2/20 0.70
SMN1; SMN2 Q16637 2/20 0.70
PTGS1 P23219 1/20 0.69
PTGS2 P35354 1/20 0.69
PKM P14618 1/20 0.67
HTT P42858 1/20 0.67
MEN1 O00255 5/20 0.66
KMT2A Q03164 5/20 0.66
KDM4E B2RXH2 2/20 0.64
MAPT P10636 1/20 0.64
LMNA P02545 1/20 0.62
GAA P10253 1/20 0.62
GPR27 Q9NS67 1/20 0.61
TP53 P04637 1/20 0.61
MAPK1 P28482 1/20 0.61
KDR P35968 1/20 0.61
NAMPT P43490 1/20 0.60
POLB P06746 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12197830 0.92 GRM4 (1.00) GRM4NPC1RAB9ASMN1; SMN2PTGS2
SCHEMBL12197854 0.88 GRM4 (0.83) GRM4NPC1RAB9ASMN1; SMN2PTGS2
SCHEMBL27180433 0.88 GRM4 (0.77) GRM4NPC1RAB9ASMN1; SMN2PKM
SCHEMBL30926765 0.88 GRM4 (0.77) GRM4NPC1RAB9ASMN1; SMN2PKM
SCHEMBL12197879 0.86 GRM4 (0.79) GRM4NPC1RAB9ASMN1; SMN2PTGS1
SCHEMBL12197845 0.85 MAPT (0.80) GRM4NPC1RAB9ASMN1; SMN2PKM
SCHEMBL1970027 0.85 GRM4 (1.00) GRM4NPC1RAB9ASMN1; SMN2PKM
SCHEMBL12197853 0.84 GRM4 (0.80) GRM4NPC1RAB9ASMN1; SMN2PTGS2
SCHEMBL17593231 0.83 POLB (0.78) SMN1; SMN2MEN1KMT2AKDM4ELMNA
SCHEMBL12197835 0.82 NPC1 (1.00) GRM4NPC1RAB9ASMN1; SMN2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110243844-A1 SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS MERCK SHARP & DOHME CORP. 2011-10-06 US disclosed
US-20110243844-A1 SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS MERCK SHARP & DOHME CORP. 2011-10-06 US disclosed
WO-2010033350-A1 SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS MERCK & CO., INC. (US) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110243844-A1 SULFONAMIDE DERIVATIVE METABOTROPIC GLUTAMATE R4 LIGANDS GRM4, GRIA4, GRM1 GRM4 1/4885NPC1 2618/4885RAB9A 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.